A Phase 1b, Randomized, Subject And Investigator-Blinded, Sponsor-Open, Placebo Controlled, Cross-Over Efficacy, Safety And Tolerability Study Of Single Oral Split Dose Administration Of PF-06412562 In Subjects With Parkinson's Disease

Trial Profile

A Phase 1b, Randomized, Subject And Investigator-Blinded, Sponsor-Open, Placebo Controlled, Cross-Over Efficacy, Safety And Tolerability Study Of Single Oral Split Dose Administration Of PF-06412562 In Subjects With Parkinson's Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Sep 2015

At a glance

  • Drugs PF 6412562 (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 02 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Apr 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 26 Feb 2014 Planned initiation date changed from 1 Jan 2014 to 1 Mar 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top